The group office will ask for efforts to recover the losses caused by the epidemic.
Release time:
2020-07-15
From February 10, most of the group's subordinate enterprises have resumed work one after another. In view of the current epidemic prevention and control situation and the resumption of work by enterprises, the group office meeting held on February 14 proposed that the epidemic prevention and control should be done thoroughly and deeply, the production and operation should be done as early as possible, the work of enterprises should be restored to the right track as soon as possible, and efforts should be made to complete the annual production target.
Since the resumption of work at the Group's corporate headquarters and Peak Pharmaceuticals on February 10, the leaders of the Group have gone deep into the various enterprises in gold to understand the prevention and control of the epidemic and the resumption of work and production. Due to the differences in the epidemic situation in different provinces, government departments have different requirements for enterprises to resume work, but as the epidemic prevention and control situation is not yet clear, the Group's enterprises in general have insufficient staff to work, the operating rate is not high, the market is stagnant, production and operation have been seriously affected. In response to this situation, the Group Office will request the resumption of work and epidemic prevention and control work in the near future. The
meeting pointed out that the current epidemic situation in other provinces except Hubei Province has basically stabilized. Therefore, except for Daye Peak, all enterprises must do a good job in daily prevention and control work while putting production and operation on the right track as soon as possible. All enterprises should carefully compare with the advanced enterprises in the same industry, make full use of the methods and management means such as fine management, benchmarking management, comprehensive budget and standardized management, focus on basic management, consolidate the foundation of enterprise development, and form a management improvement normal mechanism with peak characteristics. The
meeting requires that all enterprises should further refine their work indicators, find out the gap against benchmarks, find out the direction of their efforts, and make up for the gap through tackling key problems and innovations; further promote the optimization of organizational structure and personnel, and promote the improvement of production management efficiency; Take advantage of the current market that has not yet recovered and the production pressure is relatively small to rectify the existing technology and equipment on site, to ensure that the situation is normal, the situation can be quickly opened; to overcome the unfavorable factors of the current economic downturn, to maintain good customer relations and the market; enterprises should resume marketing work as soon as possible according to the different conditions of different regions.
meeting stressed that the current state has introduced some measures for enterprises to resume work, after the epidemic will inevitably formulate corresponding policies for the recovery of the economy, enterprises face the market environment, policy environment will be affected, enterprises should pay close attention to the changes in relevant policies, timely formulation of countermeasures. In the current critical period of epidemic prevention and control and resumption of work and production, we should adhere to the principle of "simultaneous development of (resumption of) work and prevention (epidemic)", make the prevention and control work thorough and deep, make the production and operation early and excellent, comprehensively consider the annual work plan, build confidence, do solid work, return all kinds of operation and management work to the normal track as soon as possible, strive to snatch back the losses caused by the epidemic, and strive to complete the annual production and operation target. (this newspaper reporter)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page